For the quarter ending 2025-12-31, ELTP made $31,589,251 in revenue. $18,593,806 in net income. Net profit margin of 58.86%.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Total revenue | 31,589,251 | 36,321,704 | 40,211,097 | 31,996,273 |
| Cost of manufacturing | 18,636,076 | 22,248,671 | 12,985,127 | 14,701,165 |
| Gross profit | 12,953,175 | 14,073,033 | 27,225,970 | 17,295,108 |
| Research and development | 1,040,665 | 1,385,306 | 1,674,964 | 2,041,413 |
| General and administrative | 2,466,336 | 4,029,199 | 3,404,084 | 2,034,416 |
| Impairment of intangible assets | - | - | - | 801,713 |
| Non-cash compensation through issuance of stock options | 45,096 | 49,918 | 52,329 | 52,329 |
| Depreciation and amortization | 388,135 | 394,864 | 394,886 | 409,865 |
| Total operating expenses | 3,940,232 | 5,859,287 | 5,526,263 | 6,141,449 |
| Income from operations | 9,012,943 | 8,213,746 | 21,699,707 | 11,153,659 |
| Change in fair value of derivative financial instruments - warrants | 11,817,375 | 7,519,649 | -22,109,537 | 8,365,831 |
| Other income | - | 34,500 | 0 | - |
| Interest expense and amortization of debt issuance costs | 80,204 | 82,470 | 158,926 | 188,843 |
| Interest income | 83,602 | 4,922 | 4,542 | 4,560 |
| Other income (expense), net | 11,820,773 | 7,476,601 | -22,263,921 | 8,118,240 |
| Income (loss) before income taxes | 20,833,716 | 15,690,347 | -564,214 | 19,271,899 |
| Income tax expense | 2,239,910 | 1,987,940 | 5,320,501 | 2,274,162 |
| Net income (loss) | 18,593,806 | 13,702,407 | -5,884,715 | 16,997,737 |
| Basic net income (loss) per share | 0.02 | 0.01 | -0.01 | - |
| Basic weighted average common stock outstanding | 1,074,115,101 | 1,071,897,174 | 1,068,363,108 | -2,136,528,956 |
| Diluted net income (loss) per share | 0.01 | 0.01 | -0.01 | - |
| Diluted weighted average common stock outstanding | 1,140,876,178 | 1,141,536,381 | 1,068,363,108 | -2,144,506,052 |
ELITE PHARMACEUTICALS INC NV (ELTP)
ELITE PHARMACEUTICALS INC NV (ELTP)